Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
- 4 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 43 (8), 711-725
- https://doi.org/10.1007/s40264-020-00938-z
Abstract
The introduction of novel, small-molecule Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics. This review aimed to critically assess the drug–drug interaction potential of tofacitinib, baricitinib and upadacitinib and provide a balanced perspective for choosing the most appropriate Janus kinase inhibitor based on the needs of patients with rheumatoid arthritis including co-medications and renal/hepatic impairment status. Based on the critical assessment, all three approved Janus kinase inhibitors generally provide a favourable opportunity for co-prescription with a plethora of drugs. While cytochrome P450 3A4-related inhibition or induction altered the exposures (area under the curve) of tofacitinib and upadacitinib, it did not impact the exposure of baricitinib. Transporter drug–drug interaction studies revealed that the disposition of baricitinib was altered with certain transporter inhibitors as compared with either tofacitinib or upadacitinib. Adjustment of tofacitinib or baricitinib dosages but not that of upadacitinib is required with the progression of renal impairment from a mild to a severe condition. While the dosage of tofacitinib needs to be adjusted for patients with moderate hepatic impairment status, it is not the case for either baricitinib or upadacitinib. Assessment of the drug–drug interaction potential suggests that tofacitinib, baricitinib and upadacitinib generally show a favourable disposition with no perpetrator activity; however, as victim drugs, they show subtle pharmacokinetic differences that may be considered during polypharmacy. Moreover, careful choice of the three drugs could be made in patients with rheumatoid arthritis with varying degrees of renal/hepatic impairments.Keywords
This publication has 63 references indexed in Scilit:
- JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapyExpert Opinion on Investigational Drugs, 2012
- Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro dataBritish Journal of Clinical Pharmacology, 2012
- The Pathogenesis of Rheumatoid ArthritisThe New England Journal of Medicine, 2011
- A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy ParticipantsThe Journal of Clinical Pharmacology, 2011
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics, 2011
- Rheumatoid arthritisThe Lancet, 2009
- Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating MetabolitesChemical Research in Toxicology, 2009
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Cytokines, Inflammation, and PainInternational Anesthesiology Clinics, 2007
- Pharmacokinetic Drug Interactions Involving 17??-EthinylestradiolClinical Pharmacokinetics, 2007